GfK drops TNS bid

Share this article:

A proposed acquisition of TNS by GfK was canceled, according to an article published in Daily Research News Online.

An original “merger of equals” between the two market research firms was announced last April. According to the Daily Research News Online article, the merger was thwarted by a WPP bid of $2.1 billion to acquire TNS, which was preliminarily rejected on the grounds that it “substantially undervalued” the company.

According to a GfK company statement, the management board "has concluded that the terms of the financing available did not enable a sufficiently compelling alternative cash offer to be made for TNS that was also economically in the best interests of the GfK shareholders."

Marion Eisenblatter, a GfK spokesperson, said the company will continue looking for aquisitions in the future, but probably won't consider firms as large as TNS.

GfK is a market research firm employing approximately 9,300 people worldwide. The initial merger of equals with TNS would have created GfK-TNS, with global head offices in London and Germany.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...